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Abstract
McNichol, Ryan Matthew. M.S., Department of Microbiology and Immunology, Wright
State University, 2007.
Characteristics of a Foamy Virus-Derived Vector that allow for safe autologous gene
therapy to correct Leukocyte Adhesion Deficiency Type 1.
The hematopoeitic stem cell is a prime target for gene therapy in the attempt to correct a
number of single gene inherited genetic defects that affect the immune system. In persons
affected by leukocyte adhesion deficiency type 1 (LAD-1) the gene for the Beta-2 subunit of the
integrin molecule is mutated. This autosomal recessive gene defect yields a phenotype with little
or no beta-2 integrin expression on leukocytes. Beta-2 integrin expression is essential for
leukocytes to travel from the blood to the tissues to fight infection. Persons with this disease
have lowered leukocyte counts in the tissues and as a result are beset with recurrent infections
which often cause death within the first year of life. As an alternative to using sibling bone
marrow transplants, a treatment using retroviral vectors in autologous gene therapy is being
studied to correct the disease. Problems surrounding retroviral vectors include 1) a dependence
on cell division for integration, 2) short term transgene expression, 3) insertional mutagenesis
and 4) the potential of becoming replication competent. The latest alternative in the treatment of
LAD-1 is the use of vectors derived from human foamy viruses. These viruses show no human
pathogenicity. The foamy viruses have displayed promising integration patterns in cells and are
able to survive in quiescent cells that will later divide. Furthermore, these viruses can be
modified to become replication incompetent. Using the promoter sequence for the integrin
subunit CD18 to direct transgene expression will further increase the safety of this vector in
treating LAD-1.
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INTRODUCTION
Hematopoeitic stem cells (HSCs) are the self renewing adult stem cell population
in the bone marrow which gives rise to all the cell types in the blood. The HSCs undergo
asymmetric cell division and eventually give rise to lymphoid and myeloid progenitors.
The lymphoid progenitors divide and further differentiate to become the thymocytes in
the thymus, the B-cell precursors in the bone marrow, and the natural killer cells. The
myeloid progenitors also divide and further differentiate to become mast cells,
neutrophils, eosinophils, basophils, erythrocytes, the platelet producing megakaryocytes
and the blood monocytes which give rise to tissue macrophages. Dendritic cells arise
from both the lymphoid and myeloid progenitors (29, 47).

Figure 1. Origin of the Cells of the Immune System

Adapted from http://stemcells.nih.gov/info/scireport/chapter5.asp
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The immune cells, red blood cells and megakaryocytes derived from HSCs will
sometimes have malfunctioning proteins or even lack certain cell surface and intracellular
signaling proteins. The result is a variety of blood diseases. These problems make the
HSC population an attractive target for viral vector-mediated gene therapy to correct a
number of genetically inherited diseases. Some of these target diseases include sickle
cell anemia (49), beta-thalassemia (44), adenosine deaminase-deficient severe combined
immunodeficiency (ADA SCID) (27), X-linked SCID (16), X-linked
agammaglobulinemia (67), chronic granulomatous disease (22), Wiskott-Aldrich
syndrome (55), and leukocyte adhesion deficiency type 1 (LAD-1) (13), a very rare
disorder in which neutrophil migration is impaired.

NEUTROPHILS
The cells that are primarily responsible for clearing infectious agents from the
body are the phagocytes, the macrophages and the neutrophils. The most abundant of
these cell types is the neutrophil, which comprises over 50% of the total circulating white
blood cells. Due to their short 12-16 day life span neutrophils are produced at a rate of
100 billion cells per day (14, 25, 66). Three billion of these cells daily travel to the
mucosal tissues of the nose and throat to protect these areas of high pathogen exposure.
This cell type is also known as the polymorphonuclear neutrophil leukocyte and is easily
distinguished from eosinophils and basophils by its multilobed nucleus (figure 2) (29).
Neutrophils originate in the bone marrow and circulate in the blood until they are
summoned to enter infected tissue by complement proteins or inflammatory signals from
the site of an infection. Neutrophils move from the blood stream to the tissue by
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squeezing between endothelial cells of the blood vessel wall, a process called diapedesis,
and follow a chemokine gradient to the site of infection to phagocytose pathogenic
invaders. The engulfed pathogens are safely destroyed by reactive oxygen species and
microbicidal proteins while causing little or no damage to surrounding tissue (29, 47, 66).
After having carried out their function, neutrophils then begin to undergo apoptosis and
are ingested by macrophages. The average lifespan of a mature neutrophil is 12-16 days
(14, 25, 66).

Figure 2. Diagram and Light Microscope Image of a Neutrophil

Adapted from Parham, The Immune System 2nd ed. 2005

Neutrophil Development
The development of a Neutrophil in the bone marrow from its most immature
precursor to a fully functional mature phagocyte includes six stages. The stages are:
Myeloblast → Promyelocyte → Myelocyte → Metamyelocyte → Band →Mature
Polymorphonuclear Neutrophil (Figure 3) (5). The first three stages of development are
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mitotic while the last three are not mitotic. During the promyelocyte, myelocyte,
metamyelocyte and band stages of development the azurophilic, specific and gelatinase
granules are produced. The azurophilic and specific granules are produced in the
promyelocyte and myelocyte stages respectively and contain mainly the potent
microbicidal proteins that the neutrophil uses to destroy pathogens. The granules act on
the invading pathogen in one of two ways. The granules are delivered to the phagosome
or they are exocytosed to destroy foreign invaders in the extracellular matrix. The
gelatinase granules are composed primarily of metalloproteases capable of cleaving the
constituents of the basement membrane and extracellular matrix and allow the neutrophil
to move out of the blood stream and migrate through the tissues (20).
After development, neutrophils can be found in the bone marrow, the blood
stream, or in the tissues. In the blood, neutrophils are classified as one of two types based
on their relationship to the vascular endothelial wall. The neutrophils which move slowly
through circulation making brief, reversible, attachments to the blood vessel wall are
called marginal neutrophils while freely circulating neutrophils are referred to as
circulating neutrophils (5, 14, 25).
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Figure 3. Development of a Neutrophil

Adapted from Bainton et al. 1971

Neutrophil Migration
Mature neutrophils in the bone marrow are summoned into the blood by the
inflammatory cytokines interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis
factor-α (TNF-α). Neutrophils in the blood can be converted from circulating neutrophils
to marginal neutrophils through the function of selectins. Chemokines and cytokines
released by tissue macrophages induce the expression of L-selectin on neutrophils and Eand P-selectins on vascular endothelial cells at the post-capillary venule. Selectins make
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transient attachments to their carbohydrate ligands on an opposing surface to mediate
“neutrophil rolling” where neutrophils roll along the blood vessel wall prior to migration
into tissues. E- and P-selectins bind to the carbodrate molecules sialyl-Lewis X and Pselectin Glycoprotein Ligand-1 (PSGL-1) of neutrophils respectively. L-selectins bind to
sulfated sialyl-Lewis X of the endothelial cell surface. Rolling is a prerequisite for
neutrophils that migrate from the blood to the site of infected or inflamed tissue (14, 25,
29, 47, 66).
The next step in migration involves the interaction of integrin molecules on the
neutrophil with intercellular adhesion molecules (ICAMs) on the endothelial cell. This
interaction mediates the events of arrest and migration across the blood vessel wall at the
site of infection or inflammation. The integrins CD11a/CD18 (leukocyte functional
antigen-1 (LFA-1)), CD11b/CD18 (Mac-1 or complement receptor 3 (CR3)) and
CD11c/CD18 (p150,95) are composed of an alpha protein (CD11) and a beta-2 protein
(CD18). These are the three main integrins involved in arresting the neutrophil. The
beta-2 protein of this pair of integrin molecules assumes an active form when neutrophils
are exposed to inflammatory chemoattractants such as C5a, and IL-8. These
chemoattractants not only increase the integrin affinity for ICAMs but they also induce
the neutrophil to discard L-selectin molecules. On the endothelial cell, the ICAM-1 is
upregulated mainly by the inflammatory cytokines interleukin-1 (IL-1) and tumor
necrosis factor-α (TNF-α). The activated integrin molecule attached to the ICAM then
brings the rolling neutrophil to rest and sets the stage for transmigration across the
endothelial wall (14, 25, 29, 47, 66).
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At the stage of arrest, the neutrophil crosses the endothelial wall through the
interaction of platelet endothelial cell adhesion molecule-1 (PECAM-1) (also known as
CD31). PECAM-1 is expressed both on neutrophils and at the junction between
endothelial cells. At this intercellular junction, CD31 on neutrophils binds to CD31 on
the endothelial cell to perform transmigration (25, 29, 47, 66).

Figure 4. Extravasation of a Neutrophil From the Blood to the Tissues

Adapted from Parham, 2001

At this point the only remaining barrier between the neutrophil and the intended
tissue is the basement membrane of the post capillary venule wall. The activated
neutrophil releases enzymes from its gelatinase granules known as collagenolytic
metalloproteases which are responsible for cleaving the basement membrane of the blood
vessel wall (20).
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Following the neutrophil entry into the tissues it migrates to the foreign invader
that elicited its migration. The neutrophil travels to the pathogen along a chemical
gradient by an amoeboid movement. Some of the chemoattractants for which the
neutrophil possesses receptors are C5a (a product of the complement cascade), C5a des
Arg (a processed form of C5a), interleukin-8 (IL-8) (also known as the chemokine
CXCL8) and proteins containing N-formylmethionine (an amino acid found only on
bacterial proteins) (66).

Phagocytosis
A neutrophil expresses a variety of cell surface molecules by which it recognizes
foreign invaders and discriminates against human tissue. Infectious bacteria possess
pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) on
their surface. The neutrophil will bind to LPS by its CD14 and CR4 receptors to initiate
phagocytosis. The neutrophil can also bind to opsonins such as complement protein and
antibody which coat the surface of the pathogen. Complement receptor 3 (also known as
CD11b/CD18) binds to the abundant complement protein C3b while the Fc receptor
binds to the Fc region of pathogen bound antibody (14, 25, 29, 47, 66).
The process of engulfment (endocytosis) follows pathogen binding and
psuedopods of the neutrophil project out around the bound pathogen and fuse together to
form a phagosome, a membrane bound chamber within the neutrophil. It is in the
phagosome that killing and degradation take place. Many mechanisms are responsible
for dismantling the engulfed pathogen, but they can be simplified into two main
categories: those processes that involve microbicidal proteins released during the
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formation of the phagolysosome and those that involve the generation of reactive oxygen
species (ROS). Generation of ROS is initiated when the neutrophil’s integrin molecule
binds to an ICAM (66).

Apoptosis and Clearance
The neutrophil’s lifespan ends with programmed cell death. During this process
the phospholipid, phosphatidyl-serine (PS) is exposed to the outer leaflet of the
neutrophil membrane. The PS receptors of the macrophage bind to the exposed PS and
engulf the dead neutrophil (14).
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LEUKOCYTE ADHESION DEFICIENCY TYPE 1
Leukocyte adhesion deficiency type 1 (LAD-1) is a defect in which the expression
of the three main leukocyte integrin molecules LFA-1, Mac-1 and p150,95 is decreased,
completely absent, or expressed but nonfunctional. These molecules are responsible for
allowing leukocytes to firmly attach to blood vessel walls and transmigrate into the
tissues. The integrin molecules allow leukocytes to bind to each other and also to
intercellular adhesion molecule-1 (ICAM-1) on activated endothelial cells of the post
capillary wall. These three integrin molecules consist of different alpha-1 subunits
(CD11a in LFA-1, CD11b in Mac-1, CD11c in p150,95) and a common beta-2 subunit
(CD18) which pairs with the alpha subunit in the assembly of each of these molecules.
The alpha and beta subunits are separately translated, undergo carbohydrate additions,
and paired with each other for transport to the cell surface (53).

Figure 5. Diagram of a Beta-2 Integrin Molecule with Alpha and Beta Subunits

Adapted from www.medicine.ox.ac.uk/ndog/mardon/integrin.htm
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The gene for the beta-2 subunit contains 16 exons and stretches about 40
kilobases. Along this region of DNA a variety of mutations may occur. Three main
types of mutations give rise to the disease phenotype. The first type of mutation alters
the region of the beta-2 subunit known as the I-domain which is encoded by exons 5-9 of
the gene. Such a mutation may decrease the ability of the beta-2 subunit to pair with one
of its three alpha partners, but more importantly will decrease the ability of the beta-2
integrin to bind to its ICAM ligands (6). The second type of mutation affects the 13th
exon of the beta-2 subunit gene. This region of the gene encodes for a cysteine rich
region that gives stability to the protein through multiple disulfide bonds within the beta2 subunit (51). The third type of mutation affects the ability of the beta-2 mRNA to
splice. This mutation, which can occur at any exon/intron border within the gene, alters
splice acceptor or donor sites and gives a resulting larger-than-usual mRNA molecule
which in turn is not translated into the beta-2 subunit (51).

Figure 6. Gene organization of the CD18 subunit (exons represented by black bars)

Adapted from Weitzman et al., 1991
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As stated above, in LAD-1 patients, a mutation in the gene for the common beta-2
subunit results in little or absent expression on the leukocyte cell membrane (53). The
cell types that are most affected by this mutation are the macrophages and neutrophils.
As neutrophils are clearly the most abundant white blood cell type, their levels in blood
and tissue are used to measure disease severity. B and T lymphocytes have other
adhesion molecules which can compensate for the loss CD11/CD18 heterodimers and are
thus able to perform adhesion in LAD-1 patients (3).
The percentage of CD18 protein expression corresponds with the level of disease
severity. Those patients that express less than 1% of normal levels of functional integrins
are said to have the severe form of the disease, whereas patients whose levels are in the
1% to 10% range have the mild form of the disease. Those born with severe LAD-1
often die by the age of 1 and those with milder forms of the disease rarely live beyond
their 40s (41, 42). Persons who are heterozygous for a LAD-1 mutation have about 50%
of blood neutrophils expressing functional integrins and exhibit no disease phenotype
(41).
Patients with LAD-1 usually have chronic bacterial infections with
Staphylococcus aureus and Escherichia coli, and fungal infections like Candida and
Aspergillus (42). Infections of this nature necessitate regular antibiotic/antifungal
treatment and frequent transfusions with normal granulocytes. Another treatment option
is bone marrow transplantation, but as with granulocyte transfusion, there always exists
the risk of graft rejection through alloantibody formation (3).
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GENE THERAPY HISTORY OF LAD-1
Before gene therapy could be considered to treat LAD-1, researchers needed to
uncover the molecular basis of the disease and the gene or genes affected. The molecular
basis was discovered when a hybrid experiment was performed with T cells from a
patient with LAD-1 and normal mouse T cells. Before fusion of the cells, the T cells
from the LAD-1 patient expressed neither the alpha nor the beta subunit of the integrin
LFA-1 on their surface. After fusion, it was apparent that the human alpha protein
coupled with the mouse beta protein to form a hybrid LFA-1 integrin molecule that could
be expressed at the cell surface of the hybrid cell. None of the resulting hybrids in this
study expressed the human derived beta-2 subunit. This finding allowed researchers to
trace the genetic defect of LAD-1 to the gene encoding the beta-2 subunit of the integrin
molecule (43). The gene for this common beta-2 subunit was later discovered to be on
chromosome 21 (64). The gene spans about 40 kilobases and contains 16 exons, but its
coding sequence alone was determined to be a mere 2.3 kilobases (64). The largest
transgene sequence that can be accommodated by a retroviral vector is 9.2 kilobases (58);
therefore, LAD-1 is an ideal candidate for retroviral-mediated gene therapy (4).
Based on the above findings, some laboratories began to use various viral vectors
to transfect and transduce the CD18 gene into cells from LAD-1 patients. These early
studies relied on EBV-, RSV-, and Moloney MLV-based vector systems and EBV
transformed cell lines derived from LAD-1 subjects (4, 11, 26, 65). The next step toward
correction of this disease began with a clinical trial where the Moloney MLV-based
vector system was used to target the CD34+ cells from two patients with the severe form
of LAD-1. The CD34+ cells were obtained and purified from the peripheral blood
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through G-CSF-induced mobilization followed by apheresis and CD34+ HSC
purification. Researchers attempted to transduce the hematopoeitic stem cells of these
LAD-1 patients ex vivo and then reintroduce these cells into these patients, with the hope
that their own gene-corrected stem cells would give rise to gene corrected progeny in
vivo. These patients both exhibited a temporary increase of more than double the
percentage CD18+ neutrophils in the blood and a temporary improvement of disease
phenotype. These researchers concluded that the procedure with this vector system
required further enhancement and modification (personal communication with Dennis
Hickstein and Thomas Bauer, unpublished results from 1999). Later, this lab concluded
that the temporary cure seen in this patient was due to the fact that the oncoretroviral
vector requires cell division to integrate its target cell (10). Therefore, there are two
possible explanations for this failed gene therapy trial. 1) The cell that these vectors
transduced was not the HSC but the transient myeloid progenitor. 2) It is possible that
this vector did transduce the HSC but that the forced ex vivo cell division by multiple
growth factors caused both of this cell’s daughters to become committed myeloid
progenitors (23).

FURTHER STEPS IN GENE THERAPY TREATMENT OF LAD-1
At present, dogs with Canine Leukocyte Adhesion Deficiency type 1 (CLAD-1)
are being used to test autologous HSC therapy in hope that the therapy could be
successfully used in humans. In the treatment of CLAD-1, bone marrow transplantation
has been used to successfully correct CLAD-1. While bone transplantation has a history
of failure with human LAD-1 patients (57), this large animal bone marrow
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transplantation revealed that only a small increase in the number of CD18 expressing
neutrophils is sufficient to reverse or improve the disease phenotype (8). Persons who
are heterozygous for a LAD-1 mutation will exhibit no disease phenotype and these
persons express at most 50% of the normal amounts of CD18 on their neutrophils (41),
while those with the most moderate phenotype of the disease can express up to 31% of
normal levels on their neutrophils (2). In view of these points, it is clear that this disease
only requires partial restoration of normal numbers of CD18 expression on neutrophils in
order for the disease phenotype to be reversed.
The goal of autologous gene therapy experiments is that the virally transduced
autologous cell (the HSC) will persist in the patients and permanently give rise to gene
corrected immune cell types to improve or reverse the disease phenotype. The only viral
vectors which are capable of this kind of cure are the retroviruses because only this
family of viruses is capable of integration into the target cell chromatin (32). This goal
has been reached in Irish Setters with CLAD on two separate occasions where two
different retroviral vectors were employed. In the first of these two studies the foamy
virus-derived vector was used to completely reverse the disease phenotype in four out of
five dogs. All four of these dogs are completely disease free and have not required
antibiotics at two years post- treatment (Personal Communication with Dennis Hickstein,
unpublished data from 2005). In another experiment, six out of 11 treated dogs had the
disease phenotype reversed or improved using an MLV-derived vector and reinfusing ex
vivo corrected HSCs. Slight increases in CD18+ neutrophil levels were maintained up to
21 months following treatment (9). HIV-1-derived vectors have also been used in
attempt to correct other blood diseases (44, 49) in small animal models, but never in
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LAD-1 studies. The lentiviruses will be discussed as they have a significant advantage
over the oncoretroviruses for delivering gene to the HSC.

The Problems with Retroviral Vectors
The preintegration complex of an MLV-derived vector is too large to pass through
the nuclear envelope of a non-dividing cell (i.e. HSCs) (59). Therefore, in order for
integration to take place using these popular vectors, HSCs must be forced to divide.
Forcing a stem cell to divide can be detrimental to the goal of achieving a permanent cure
because if the cell is exposed to growth factors for a long enough period of time the cell
may differentiate (21). Although integration will be accomplished, the daughter cells of
the HSC might be committed to myeloid or lymphoid progenitors which have a limited
lifespan in vivo. This commitment to a progenitor was the explanation for the failure of
an early LAD-1 clinical trial (10).
Retroviral vectors still remain as attractive tools for gene therapy because they are
capable of integrating genetic information into target cells. If the vector is derived from a
lentivirus, it can integrate into non-dividing cells. However, the retroviruses exhibit
preferential integration (figure 7). Preference for integration into active genes has been
seen in Beta-globin gene transduction with HIV-1-derived vectors (28, 62). Preference
for integration close to promoter sequences has also been observed in γ chain gene
transduction with MLV-derived vectors (24, 62) The dangers of the MLV integration
preference have been demonstrated in an X-linked SCID trial where 2 of 11 young
patients after having received successful HSC correction (16) later developed leukemia.
The retroviral integration in both of these leukemia patients was found near the promoter
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for the LMO-2 gene, a proto-oncogene that is normally only expressed in progenitor cells
(24).

Figure 7. Areas of Common Integration by Oncoretroviruses and Lentiviruses

Adapted from von Kalle et al. 2004

Additionally, replication competent retrovirus (RCR) may form via recombination
during vector production. While HIV-1-derived vectors have been generated that are
claimed to be self-inactivating, these viruses can still rebuild their promoter region even
after significant deletion (19, 68). The process involved in producing such vectors
involves much risk as a single genetic recombination event can mean the generation of
one replication competent retrovirus. Furthermore, HIV-1 and MLV do not naturally
infect HSCs and for this reason these viruses need to be psuedotyped with an envelope
protein that allows entry into this cell type. If a recombination event occurred that
produced a broad host tropic HIV-1 virus, the result could be the production of a more
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harmful virus than the pre-existing wild-type HIV-1 (18). However, such an event is
very unlikely as the genes that are used to produce these vectors are located on three or
four separate plasmids within producer cells. Nevertheless, the risks involved in
manipulating this deadly pathogen have not been completely eliminated (18).
Taken together, retroviral vectors show three major problems. 1) The
oncoretroviruses cannot infect non-dividing cells. These viruses may not survive in a
quiescent cell during the G0 and G1 phases of the cell cycle since they lack sufficient
nucleotide pools required for reverse transcription prior to nuclear entry (59). These
nucleotide pools are also required for HIV-1 as seen by the fact that they transduce
dividing cells more efficiently than quiescent cells (59). 2) The oncoretroviruses and
lentiviruses have dangerous integration preferences putting stem cells at risk for
insertional mutagenesis (62). 3) Genetic recombination puts labs at risk for producing
highly pathogenic replication competent retroviruses (RCR) (18).

Table 1. Problems With Current Retroviral Vectors

Cell Cycle
Requirement
Oncoretroviruses Mitosis

Integration
Preference
Upstream of
promoters

Lentiviruses

Within active
genes

None
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RCR?
Risk not
completely
eliminated
Risk not
completely
eliminated

FOAMY VIRUSES
The foamy viruses, named for the characteristic foamy appearance that they
produce in culture, have not been heavily researched until recently. These viruses, of the
spumavirus subfamily, are endogenous in animals and they have also been isolated from
humans. In 1971 the first human foamy virus (HFV) was isolated from the nasopharynx
of a Kenyan man. The closest characterized relative of the “HFV” is the SFVcpz isolated
from a chimpanzee species which is native to Kenya (1). It is still debated as to whether
or not there is an actual human variant of this virus. Most researchers claim that the virus
isolated from a human specimen in 1971 is possibly a primate variant that the specimen
received by animal to human transmission. Therefore, while the use of the letters HFV is
common, it should probably be called SFVcpz(hu) (38).

Figure 8. Electron Micrograph of Budding Foamy Viruses

Adapted from Hooks and Gibbs. 1975
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While having the typical gag, pol and env genes that are characteristic of all
retroviruses, these viruses are unique in that they seem to be dsDNA viruses. The reason
for this classification lies in a distinct feature of their life cycle where reverse
transcription happens just prior to budding (50, 52). Another unique feature of the foamy
virus life cycle is their gene regulation. The foamy viruses have two promoters, the LTR
and an internal promoter (IP) near the end of the env gene. Both promoters are driven by
the non-structural tas (transactivator of spumavirus) protein (50). This protein is also
known as the bel-1 gene product (figure 8).

Figure 9. The Human Foamy Virus Genome

Adapted from Vassilopoulos et al. 2001

While the IP has a basal level of activity the LTR is transcriptionally inactive
without tas binding (40). The fact that the LTRs are transcriptionally inactive without tas
is an excellent safety feature in light of this virus being a gene delivery tool. Foamy
vectors constructed without the tas protein are unable to induce expression of nearby
genes (7). Foamy viruses further deviate from the other retroviruses in that many virions
never become extracellular viruses but remain associated with the plasma membrane;
their foamy appearance in culture results from syncytial formation (39). Another unique
20

feature of the foamy virus when compared to other retroviruses is their co-requirement of
gag and env for budding and infectivity (37). The env protein is processed into three
subunits after translation: a leader peptide (LP) at the N-terminus, a surface subunit (SU)
and a transmembrane subunit (TM). The env protein is processed by cellular furin-like
cellular proteases and must be cleaved at least into SU and TM subunits to be capable of
producing infection. The LP of env and the N-terminus of gag interact with each other.
This interaction is required in order for HFV capsids to be incorporated into the HFV
envelope (37).

Figure 10. The Life Cycle of the Human Foamy Virus

Adapted from Linial 1999
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Foamy Virus Vectors: Advantages
Foamy viruses have been reported to persist in humans for up to 20 years without
any pathogenic activity. A number of comprehensive studies, each of which used several
assays to confirm the presence of the virus (Table 2), have failed to attribute any disease
condition to the virus (45). Such a quality makes this virus an excellent choice as a gene
therapy vector.

Table 2. Disease Association with Foamy Viruses

Adapted from Meiering and Linial 200l

Foamy virus vectors have cell cycle requirements that are lower than the MLVderived vectors, which require cell division, yet higher than the HIV-1-derived vectors,
which do not require cell division. Another suitable quality of foamy viruses is their
ability to persist at the microtubule organizing center (MTOC) of non-dividing cell types
22

that will divide later (36, 59, 61). This ability to survive in the G0 and G1 cell cycle
environment is due to fact that these viruses have already reverse transcribed and do not
require any cellular nucleotide pools before entry into the nucleus (59). In order to
integrate genetic information, they only require cell cycle progression into the G1/S phase
(48, 59). The events taking place that allow the preintegration complex to migrate
through the Ran GTPase-controlled nuclear pore complex at G1/S phase are still a
mystery (56). However, it is known that prior to nuclear entry, FV gag processing and
viral capsid disassembly occur and this gag activity is totally dependent on some
unknown cellular factor which is probably linked with cell cycle progression into G1/S at
the MTOC (figure 11) (35).

Figure 11. Foamy Virus Capsid Disassembly and Nuclear Import

Adapted from Lehmann-Che et al. 2005
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An additional feature of the foamy virus vector that sets it apart from the
lentiviruses and oncoretroviruses is its integration patterns in infected cell types. In
contrast to the lentiviruses and oncoretroviruses, the foamy viruses do not show a
preference for integrating within active genes nor do they show a preference for
transcriptional start sites (46). Furthermore, the HFV vector integration with respect to
the LMO-2 proto-oncogene was about 700 kb from the gene’s start site. Although these
data appear promising, this study does not report on the effects that a constitutive
promoter would have on nearby genes (60).
The foamy viruses seem to have unique characteristics that serve as solutions to
the above three fundamental problems found in the other retroviral vectors. These
vectors 1) are non-pathogenic in humans (45), 2) they are able to persist in non-dividing
cell types in culture which will later be stimulated to divide (48, 59), 3) they appear to
have significantly reduced risk of insertional mutagenesis compared with the other
retroviral vectors (46, 60) and it is possible to generate a safe, self-inactivating vector
using these viruses (7). Based on a recent success in the treatment of CLAD in Irish
setters, the NIH is considering a clinical trial with humans who have LAD-1 and are
using a newer and presumably safer HFV-derived vector (personal communication w/
Hickstein and Bauer, unpublished data). These vectors are potentially the next great tool
to correct LAD-1 as well as a number of other genetic immunodeficiencies.
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Disadvantages of the Foamy Virus Vectors
While the foamy viruses appear to be a more suitable vector than the other
retroviruses the amount of virus that can be generated by packaging cells is quite low. A
small percentage of the virons generated within a producing cell will actually bud and
become extracellular particles. The reason for the low production of extracellular virus is
that the leader peptide of the envelope protein in foamy viruses is often ubiquitinated
during assembly and ushered to the proteasome for destruction. This leader peptide is
absolutely required for the foamy virus to bud from the cell (54). The LP is so often
ubiquitinated and destroyed, that the foamy virus is left with an incomplete env protein
that is incapable of allowing the virus to bud (54). The result is that there are many cell
membrane-associated virions and few viruses which are able to transfer gene to a target
cell. The target cell of the foamy virus vector in an autologous gene therapy experiment
to correct LAD-1 is the patient’s HSC. This cell type has a low amount of foamy virus
receptor (63). The low amount of Foamy receptor coupled with the low number of
extracellular viruses produced by a packaging cell line leaves the foamy virus with a
lower possibility of delivering the gene for the CD18 subunit into the HSC. However,
such disadvantages pale in comparison to this virus’s biosafety features and stability
within the quiescent cell.

Promoters used to Drive expression of the Beta Subunit Gene
The promoters that are most often used in retroviral vectors to direct the
expression of the gene of interest are the Cytomeglovirus (CMV) promoter, the MLV
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promoter and the phosphoglycerine kinase (PGK) promoter. A potential problem with
any retroviral vector is that using of one of these constitutive promoters has the potential
cause inappropriate expression of nearby genes. The key to solving this problem will be
the integrin promoter for the CD18 subunit gene. This promoter is myeloid tissue
specific and has been used in previous MLV-derived vector systems albeit with little
success (12).

HEMATOPOIETIC STEM CELLS: The Target Cell of the Autologous
Gene Therapy Experiment to Correct LAD-1
The CD34+ Hematopoietic stem cell is the target cell that needs to be harvested,
transfected by the retrovirus-derived vector, and reintroduced back into LAD-1 patients
(9). Therefore, it is important to understand how researchers are attempting to preserve
the “stemness” of this cell population during an ex vivo autologous gene therapy
experiment. As stated earlier, this cell population may differentiate in the presence of
growth factors ex vivo. One method that is being practiced to attempt to ensure that the
trandsduced HSCs retain their “stemness” is a shorter transduction protocol. The
duration of these protocols when using retrovirus-derived vectors have been reported to
be as short as 24 hours (9) with MLV vectors, 18 (33) and 10 hours (30, 31) when using
FV vectors, and even 1hour when using HIV vectors (34). The results of all these studies
were that gene corrected progeny could be observed long after the stem cell transduction
and reinfusion. However, just the fact that these cells are exposed to growth factors
could diminish their repopulating capacity even if these cells remain in the G0 phase of
the cell cycle (23). Since the FV vectors do not need circulating nucleotide pools (59)
and are able to survive as a stable transduction intermediate at the microtubule organizing
26

center (MTOC) for at least 30 days in quiescent cells (36) it is not necessary to even
expose HSCs to growth factors when using this vector. While the HSCs normally divide
on average once every 30 days in the normal bone marrow microenvironment (15, 17),
reinfusion of gene corrected HSCs could prompt them to cycle earlier, allowing the FV
vector to enter the nucleus (36). Therefore, the use of a FV vector eliminates the need to
place the HSCs in conditions that will jeopardize their long-term repopulating capacity.
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Possible Vector Design and Experimental Diagram

Figure 12. Foamy Virus Vector Production and Transduction
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CONCLUSIONS
In the near future LAD-1 patients should benefit from the use of Foamy Virusderived vectors in autologous gene therapy. This retrovirus is non-pathogenic and able to
integrate genetic information into the chromosome for long term gene expression. Also,
this virus has a unique cell cycle requirement that will allow hematopoietic stem cells to
maintain their “stemness”. Forced division of the stem cell in vitro may cause it to
become a progenitor with a limited life span, leading to a mere temporary disease
correction. Furthermore, some single gene blood diseases require a complete correction
to reverse the phenotype of the disease. LAD-1 is an autosomal recessive genetic defect
and will require at most 50% of normal levels of CD18 expression on neutrophils in order
for the disease phenotype to be reversed. In addressing the matter of insertional
mutagenesis, the FV LTRs are inactive in the absence of the tas protein. These vectors
will be unable to cause an inappropriate overexpression of nearby genes. In addition,
foamy virus vectors that have a tissue specific CD18 integrin promoter will be
exceptionally safer than those possessing constitutive promoters used in previous studies.
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